Investigating the effects of aromatase inhibitors on the musculoskeletal system
Aromatase Inhibitors (AIs) are a standard of care for the adjuvant treatment of hormone responsive early carcinoma of the breast as demonstrated in a number of large international phase III randomised trials. Arthralgia was a somewhat unexpected side effect of this class of agents and has proven to...
Main Author: | Shujja-Ud-Din, Omar S. |
---|---|
Other Authors: | Coleman, Robert E. ; Dodwell, David |
Published: |
University of Sheffield
2014
|
Subjects: | |
Online Access: | http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.651256 |
Similar Items
-
Musculoskeletal Adverse Events Associated with Adjuvant Aromatase Inhibitors
by: Qamar J. Khan, et al.
Published: (2010-01-01) -
Aromatase Inhibitor-Associated Musculoskeletal Syndrome: Understanding Mechanisms and Management
by: Tara Hyder, et al.
Published: (2021-07-01) -
Effects of aromatase inhibitors on aromatase in breast
by: Vidya, Raghavan
Published: (2009) -
Aromatase Inhibitors—Induced Musculoskeletal Disorders: Current Knowledge on Clinical and Molecular Aspects
by: Sara Tenti, et al.
Published: (2020-08-01) -
Aromatase and CDK4/6 Inhibitor-Induced Musculoskeletal Symptoms: A Systematic Review
by: Angeliki Andrikopoulou, et al.
Published: (2021-01-01)